Both sorafenib and mammalian target of rapamycin inhibitor (mTORi) have antitumor effects. This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) recurrence. We performed a laboratory study using sorafenib and mTORi and subsequently validated their survival benefit in a clinical LT setting. In the laboratory study, the HepG2.2.15 liver tumor cell line and 5 patient-derived graft HCC cell lines were used for in vitro cytotoxic studies. After treatment with everolimus and sorafenib, cell viability and apoptosis assays revealed noticeable cytotoxic effects with individual agents and augmented effects by combination therapy. An in vivo mouse study also demonstrated similar cytotoxic outcomes. In the clinical study including 232 LT recipients with HCC recurrence, the 3-month medication dropout rate was 35.6% for sorafenib administration and 23.5% for mTORi administration. Postrecurrence survival rates were not different according to sorafenib administration (P 5 0.17) but were significantly improved following mTORi administration (P < 0.001). In mTORi subgroups with and without sorafenib, there was no difference in the overall postrecurrence patient survival period (P 5 0.26), indicating an absence of synergistic or additional antitumor effect from sorafenib. The median progression-free and overall survival period was 6.4 and 11.8 months, respectively, after sorafenib administration. Time of tumor recurrence and use of mTORi were independent risk factors. In conclusion, our laboratory study demonstrated synergistic antitumor effects of sorafenib and mTORi, but this was not reproduced in our clinical LT study. Our clinical result of mTORi administration showed improved postrecurrence survival, thus administering mTORi in LT recipients with HCC recurrence appears worthwhile. However, the antitumor effect of sorafenib on posttransplant recurrence was not determined in this retrospective study, thus requiring further studies with early start of sorafenib administration.
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Hepatocellular carcinoma (HCC) is an established indication for liver transplantation (LT).
(1) Although LT candidates are prudently selected according to the selection criteria for HCC, tumor recurrence develops in a considerable proportion of LT recipients. (2) (3) (4) (5) Posttransplant HCC recurrence is associated with poor outcomes, probably because of inevitable immunosuppression and high incidences of extrahepatic metastasis. (5, 6) HCC recurrence after LT is initially treated with various locoregional treatment modalities, but frequently, such treatments are no longer applicable because of ongoing tumor progression, and sorafenib is finally prescribed. (7) (8) (9) The therapeutic effects of sorafenib in LT recipients have been investigated in a few studies (8, 9) but are believed to be suboptimal.
Mammalian target of rapamycin inhibitor (mTORi) is frequently reported to be beneficial to reduce the risk of HCC recurrence after LT, (6, 10) but its effect on established posttransplant HCC recurrence is still unclear. (11, 12) Combination therapy with sorafenib and mTORi has been attempted because of their mechanisms of action in HCC pathogenesis despite the risk of augmented adverse effects. (11, 12) Such combination therapy has been reported to have a synergistic antitumor effect in experimental animal studies, (13, 14) but its clinical effects are still debated because of the small number of LT cases with HCC recurrence and oncological heterogeneity in the study patients. (11, 12) Thus, the present study aimed to assess the antitumor effects of sorafenib, mTORi, and their combination therapy in a laboratory-based research study and to subsequently validate them in the clinical LT setting.
Patients and Methods

STUDY DESIGN
This study comprised 2 independent investigations: a laboratory research study and a clinical LT study. To assess the antitumor effects of sorafenib, mTORi, and their combination therapy, the study candidates were divided into 4 study groups as sorafenib, mTORi, their combination, and control groups.
The laboratory research study was focused on assessment of the synergistic antitumor effects with combination therapy and included in vitro and in vivo studies on tumor growth using an established HepG2 cell line and patientderived xenograft (PDX) tumor cell lines. (15) In the clinical LT study, the survival periods after diagnosis of HCC recurrence were compared among the abovementioned 4 groups to validate the antitumor effects. These study designs are depicted in Fig. 1 modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco-BRL, Grand Island, NY).
The effects of sorafenib and everolimus were evaluated using this liver tumor cell line. To reproduce the therapeutic ranges in HCC patients and LT recipients, the in vitro drug concentration was determined to be 10 lmol/mL for sorafenib and 10 nmol/mL for everolimus after repeated titration studies (5-20 lmol/mL for sorafenib and 5-20 nmol/mL for everolimus). (16) (17) (18) (19) (20) Duration for drug exposure was set to be 20 hours.
To assess cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Duchefa, Haarlem, the Netherlands) assays were performed using 12-well plates. The optical density was assessed at 550 nm using a microplate reader (Bio-Rad, Marnes-laCoquette, France). Cell survival was expressed as the percentage of absorbance in drug-treated cells relative to that in untreated cells. The cells were also observed under a fluorescence microscope after 4 0 ,6-diamidino-2-phenylindole (DAPI)-Hoechst staining (SigmaAldrich, Poole, Dorset, United Kingdom).
Western blot assays were performed to assess hepatitis B virus X (HBx) protein expression and apoptosis. Cell extracts were separated by polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. After blocking, the membrane was incubated with a primary antibody against HBx, poly(adenosine diphosphate ribose) polymerase (PARP)-1, cleaved PARP-1, cleaved caspase 3, and actin, followed by incubation with a secondary antibody. Antibodies against HBx (ALX-804-278-C100) were purchased from Enzo Life Sciences (Farmingdale, NY); antibodies against PARP (B-10, sc-74470) and cleaved PARP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); antibodies against actin (AC-15, A3854) were purchased from Sigma-Aldrich (Poole, Dorset, UK); and antibodies against cleaved caspase 3 (Asp175, catalogue number 9664) were obtained from Cell Signaling (Danvers, MA). Proteins in samples were detected using a Supersignal pico-enhanced chemiluminescence kit (Pierce, Rockford, IL). Unless specified, cell lysates containing 20-mg protein were analyzed.
IN VITRO STUDY WITH PDX TUMOR CELL LINES
Small pieces of human HCC tissue were obtained during hepatic resection for HCC in HBV-associated patients who did not undergo any preoperative HCC treatment (n 5 5). A small tumor fragment of 0.3 g was implanted subcutaneously at the bilateral hind flanks of a nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mouse. After the confirmation of tumor growth for 3 months, the tumor was harvested and implanted to a NOD-SCID mouse. After the confirmation of stable tumor growth, the established first-generation xenograft tumor was serially implanted into NOD-SCID mice to expand the xenograft tumors. These xenograft tumors were also implanted subcutaneously into nude mice for further tumor expansion. The tumors were then harvested to establish new PDX tumor cell lines that were used to perform in vitro study for assessment of cell viability with MTT assay.
IN VIVO MOUSE STUDY USING THE HEPG2 CELL LINE
A tumor mass of HepG2.2.15 cells (0.3 g) was implanted subcutaneously at the hind flank of 6-to 8-week-old nude mice, and the mice were fed for 2 weeks for tumor growth. Thereafter, 5 mg/kg of sorafenib and 5 lg/kg of everolimus were administered orally for 3 weeks, consistent with the oral dosage used in HCC patients and LT recipients after consideration of their plasma clearance rates in the mouse models. (17) (18) (19) (20) Gross tumor morphology and 3-dimensional volume of the tumors were assessed every day, and the mice were sacrificed on day 21 of drug administration.
Western blot assays were performed to assess alphafetoprotein (AFP) expression at the harvest tumors. Cell extracts were separated by polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. After blocking, the membrane was incubated with primary antibody against AFP (C-19: sc-8108, Santa Cruz Biotechnology, Santa Cruz, CA) and actin followed by incubation with a secondary antibody.
In addition, reverse-transcription polymerase chain reaction was also performed to assess expression of HBx and covalently closed circular DNA (cccDNA) of HBV at the harvest tumors. The following primer sets were used: HBx forward, 5 0 -TGCCAACTGGATC CTT CGCGGGACGTCCTT-3 0 ; and HBx reverse,
(nucleotides 1548-1566); and cccDNA reverse, 5 0 -GCCCCAAAGCCACCCAAG-3 0 (nucleotides 1903-1886). The data were expressed as the fold change in the HBx and cccDNA levels from the harvested tumors to the normal human liver control tissues. Details of these polymerase chain reaction methods are described elsewhere. (21) In vivo mouse study using the PDX tumor cell lines were not performed because the outcomes from in vitro studies between the HepG2 cell line and PDX tumor cell lines were very similar, thus the in vivo study outcomes were anticipated to be similar to those with HepG2 cell line.
CLINICAL LT STUDY ON 232 PATIENTS WHO HAD POSTTRANSPLANT HCC RECURRENCE
The LT database at our institution was searched to identify patients who underwent LT for HCC over a 14-year period from January 2000 to December 2013. Among 3850 LT adult recipients, 1486 recipients who had preoperative diagnosis of HCC or HCC at the explant livers were selected. Of these, 232 (15.6%) recipients had posttransplant HCC recurrence until December 2015. These 232 patients were divided into 4 groups according to administration with sorafenib and mTORi (sirolimus or everolimus; Fig. 1 ). Patients who had not continued drug treatment for 3 months were not included in the corresponding drug group. Patients were followed up until February 2017 with a medical record review and assistance from the National Health Insurance Service, thereby making the overall patient follow-up period 38 months and the postrecurrence follow-up period 14 months, or until patient death. All patients were completely followed up to identify patient survival status.
All LT recipients who were diagnosed with HCC before LT or at liver explant underwent follow-up examinations every month during the first year and every 3 months thereafter. A detailed follow-up protocol based on the relative risk of HCC recurrence has been previously described. (5) The general principles of treatment for recurrent HCC lesions were applied to LT recipients with HCC recurrence. (4, 5, 22) Locoregional treatment including transarterial chemoembolization, radiofrequency ablation, radiotherapy, and surgical resection was initially attempted if indicated, but a considerable proportion of patients with advanced HCC recurrence received sorafenib as the final treatment modality. The overall and progression-free postrecurrence survival periods after sorafenib administration were measured. Meanwhile, a wide range of heterogeneity was noted in the time of treatment initiation and in the duration of sorafenib administration; thus, we decided to compare the overall postrecurrence survival period instead of the survival period after sorafenib administration. Patients with poor general condition or impaired graft liver function beyond Child-Pugh class A were not indicated for sorafenib in principle. Sorafenib administration was stopped if disease progression developed according to the modified Response Evaluation Criteria in Solid Tumors. (23) In Korea, sorafenib has been covered by social health insurance since late 2009.
Because mTORi was not included as the primary immunosuppressant during the study period at our institution, it was not commonly used before development of HCC recurrence or de novo malignancy. In contrast, it was preferentially administered to LT recipients with HCC recurrence after introducing sirolimus in 2008. Social health insurance coverage for everolimus started in early 2016 in Korea.
After HCC recurrence, the immunosuppressive (IS) regimens were changed toward lowering calcineurin inhibitor (CNI) concentration and referential use of mTORi. Especially after everolimus was available, the IS regimen was switched to be everolimus-based if its adverse effects were tolerable.
STATISTICAL ANALYSIS
Continuous variables are reported as means with standard deviation (SD) or medians with ranges and were compared using Student t test or analysis of variance. Categorical variables were compared using chi-square or Fisher's exact test, as appropriate. Survival curves were generated using the Kaplan-Meier method and were compared using log-rank test. Cox proportional hazard regression was used for multivariate analysis and presented as hazard ratio (HR) with 95% confidence interval (CI). A P value < 0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using GraphPad Prism, version 5.0 (GraphPad, La Jolla, CA) and SPSS, version 22 (IBM, New York, NY).
Results
IN VITRO CYTOTOXICITY IN THE HEPG2 CELL LINE STUDY
The MTT assay for cell survival assessment demonstrated a concentration-dependent decrease in cell survival after 20-hour treatment with 5-20 lmol/mL of sorafenib and 5-20 nmol/mL of everolimus. The greatest decrease was observed after combined treatment with sorafenib and everolimus. Noticeable differences were observed between treatment with 5 lmol/mL of sorafenib 1 5 nmol/mL of everolimus and that with 10 lmol/mL of sorafenib 1 10 lmol/mL of everolimus, but not between treatment with 10 lmol/mL of sorafenib 1 10 lmol/mL of everolimus and that with 20 lmol/mL of sorafenib 1 20 lmol/mL of everolimus ( Fig. 2A) . Thus, the drug concentrations of 10 lmol/ mL of sorafenib 1 10 lmol/mL of everolimus were used for further in vitro studies.
A microscopic assessment of the cell morphology revealed abundant apoptosis after treatment with sorafenib, everolimus, and their combination (Fig. 2B ). Fluorescence microscopy with DAPI-Hoechst staining revealed apoptosis after treatment with sorafenib or everolimus, and the highest apoptosis levels were observed after combination therapy (Fig. 2C ).
Treatment with sorafenib or everolimus led to a noticeable down-regulation of HBx expression, and the lowest expression was observed after combination therapy (Fig. 3A) . Apoptosis was assessed by staining for PARP-1, cleaved PARP-1, and cleaved caspase 3 after treatment with sorafenib or everolimus, and the highest staining was observed after combination therapy (Fig. 3B) .
IN VITRO CYTOTOXICITY IN THE PDX TUMOR CELL LINE STUDY
MTT assay in 5 PDX tumor cell lines showed that the decrease of cell viability was observed after either sorafenib or everolimus treatment and the highest decrease was observed after combination therapy, which were similar to those of the HepG2 cell line studies. The results of the first 2 PDX tumor cell lines were depicted in Fig. 3C ,D.
IN VIVO INHIBITION OF TUMOR GROWTH IN THE HEPG2 CELL LINE STUDY
Daily observations of tumor volume over 21 days revealed noticeable tumor growth after administration of sorafenib or everolimus and marked inhibition of tumor growth after combination therapy (Fig. 4A) . Gross tumor morphology at day 21 was compared (Fig. 4B) . Tumor weight at day 21 was compared among the control, sorafenib, everolimus, and combination groups, and it was greatly decreased after combination therapy (Fig. 4C) .
Expression of AFP in the tumor tissues was inhibited after administration of either sorafenib or everolimus, and maximal inhibition occurred after combination treatment (Fig. 4D) . Expression of HBx (Fig. 4E ) and HBV cccDNA (Fig. 4F) at the tumor tissues was also down-regulated after administration of either sorafenib or everolimus, and maximal decrease occurred after combination therapy.
CLINICAL PROFILES AND MEDICATION STATUS OF 232 LT RECIPIENTS WITH HCC RECURRENCE
The number of patients in the control, sorafenib, mTORi, and combination groups were 139, 16, 54, and 23, respectively (Fig. 1) . The demographics of these 4 groups are summarized in Table 1 , and their preoperative parameters were not statistically different. None of them had administered mTORi before HCC recurrence. Initially, sorafenib was administered to 118 patients, 42 (35.6%) of them dropped out within 3 months because of adverse effects, poor general condition, or rapid tumor progression. In 21 (17.8%) patients, sorafenib administration had to be stopped within the first month primarily because of the intolerably severe adverse effects even after dosage reduction. In the remaining 77 patients, sorafenib administration was maintained over a median period of 7 months (range, 3-71 months).
The mTORi was initially administered to 51 patients, 12 (23.5%) of them dropped out within 3 months because of adverse effects and other causes; mTORi administration had to be stopped in only 4 (7.8%) of these patients because of severe adverse effects despite dosage reduction of mTORi. In the remaining 39 patients, mTORi administration was maintained over a median period of 12 months (range, 3-60 months). Only sirolimus was available in Korea before 2016, which was subsequently replaced with everolimus because only everolimus was financially covered by the social health insurance in LT recipients. After insurance coverage for everolimus, the dropout rate of mTORi was lowered to 6.7% (2/30). Thus, 23 patients had used sirolimus only, 6 switched from sirolimus to everolimus, and 22 used everolimus only. None of these patients experienced overt acute rejection requiring high-dose steroid therapy; mTORi was used alone or in combination with minimal CNI or mycophenolate mofetil (MMF; Table 1 ).
LONGTERM OUTCOMES IN LT RECIPIENTS WITH HCC RECURRENCE TREATED WITH SORAFENIB AND mTORi
The overall and postrecurrence patient survival rates were 84.5% and 54.0% at 1 year, 49.6% and 28.0% at 3 years, 33.6% and 19.9% at 5 years, and 19.0% and 4.5% at 10 years, respectively (Fig. 5A,B) .
The postrecurrence survival rate differed significantly according to the recurrence time after LT (P < 0.001; Fig. 5C ); thus, patients with late recurrence 1 or 3 years posttransplant demonstrated significantly prolonged overall survival outcomes than those with earlier recurrence (P < 0.001; Fig. 5D ). The overall postrecurrence survival rate in the sorafenib group demonstrated no significant difference (P 5 0.17; Fig. 6A ). In contrast, the overall postrecurrence survival rate in the mTORi demonstrated a significant difference (P < 0.001; Fig. 6B ). The overall postrecurrence survival after combined therapy demonstrated a significant difference (P 5 0.002; Fig. 6C ). In the mTORi subgroups with and without sorafenib, there was no difference in overall postrecurrence patient survival period (P 5 0.26). Compared with the sorafenib group, the combination therapy group demonstrated a significant prolongation in overall postrecurrence patient survival period (P 5 0.006; Fig. 6D ). In the sorafenib group, the median periods for progression-free and overall patient survival after sorafenib administration were only 6.4 and 11.8 months, respectively (Fig. 6E) . These findings indicated that the antitumor effect was primarily demonstrated after mTORi administration but not after sorafenib administration.
Because there was a prognostic difference in the time of tumor recurrence, patients in the mTORi group were divided accordingly; mTORi treatment demonstrated a significant prognostic difference in patients with tumor recurrence within the first year In the sorafenib group, the overall postrecurrence survival curves according to mTORi administration were compared. (E) In the sorafenib group, the overall and progression-free survival curves after administration of sorafenib were also shown.
(P 5 0.006; Fig. 7A ), during the second and third years (P 5 0.021; Fig. 7B ), and after 3 years (P 5 0.098; Fig. 7C ). Considering the prognostic contrast was rather low because of the small number of patients in the subgroup of HCC recurrence after 3 years, these findings indicated that the beneficial antitumor effect might be present after mTORi administration regardless of the time of tumor recurrence.
RISK FACTOR ANALYSIS FOR POSTRECURRENCE PATIENT SURVIVAL
We compared the pretransplant and postrecurrence profiles for univariate analysis of postrecurrence patient survival, in which only the time of tumor recurrence and use of mTORi were statistically significant. These 2 factors were also statistically significant in multivariate analysis, as showing early tumor recurrence < 1 year (HR 5 1.96; 95% CI 5 1.58-2.92; P < 0.001) and use of mTORi (HR 5 2.25; 95% CI 5 1.41-3.59; P 5 0.001), but not for sorafenib (HR 5 1.25; 95% CI 5 0.91-1.73; P 5 0.18; Table 2 ).
Discussion
Sorafenib is a multikinase inhibitor with therapeutic efficacy against HCC. (24, 25) It blocks tumor cell proliferation by targeting the Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway; exerts an anti-angiogenic effect by targeting the tyrosine kinases vascular endothelial growth factor (VEGF) receptor 2, VEGF receptor 3, plateletderived growth factor receptor b, Ret, and c-kit; and inhibits phospho-eIF4E and MCL1 protein. (24) (25) (26) Although sorafenib noticeably improves the survival of patients with advanced HCC, (27, 28) its potential mechanisms of action that induce clinical benefits are not yet well known. It is not suggested to use sorafenib as an adjuvant setting for HCC following hepatic resection or ablation. (29) Furthermore, its therapeutic effect on posttransplant HCC recurrence is still largely unknown. (8, 9) mTORi has the dual properties of IS and antitumor effects. Its IS effects are induced by the inhibition of interleukin (IL) 2-mediated T cell proliferation, (30) unlike those of CNIs that prevent calcineurin from activating IL2 production. Its antitumor effects are induced by inhibiting cell growth and angiogenesis, and it is clinically used for several malignancies. (31) An in vivo study revealed that more effective antitumoral properties of everolimus, eventual risk of proangiogenic tumoral properties and nephrotoxicity of tacrolimus, and proproliferative properties of sirolimus in tumors developed in nude mice. (32) It is also reported that sorafenib and everolimus have differential effects on HepG2 cells. Sorafenib preferentially affects glycerophospholipid and purine metabolism, whereas the addition of everolimus preferentially affects pyruvate, amino acid, and glucose metabolism. This phenomenon may explain the synergistic effects of sorafenibeverolimus combination therapy observed in vivo. (33) An analysis of the high-volume data from the Scientific Registry of Transplant Recipients has revealed that mTORi-based IS therapy is associated with improved survival after LT for HCC, but it has also revealed a trend toward lower survival rates in non-HCC recipients, thus confirming the specificity of its beneficial impact on cancer. (6) Everolimus is effective and is associated with a low rate of HCC recurrence in LT recipients. (34) (35) (36) However, so far, a majority of clinical LT studies have focused on prevention of HCC recurrence but not on the treatment of established HCC recurrence. Although we preferentially switched the primary immunosuppressant toward mTORi after HCC recurrence and de novo malignancy, there is still a lack of strong evidence supporting IS regimen using mTORi. (34) (35) (36) (37) It is difficult to quantify the antitumor effect of sorafenib and mTORi in the clinical setting of LT recipients with HCC recurrence because of the small number of LT cases with HCC recurrence and oncological heterogeneity in the study patients. (11, 12) Therefore, we needed to confirm the antitumor effects of these agents in a controlled in vivo animal study. Our present study clearly demonstrated that the antitumor effects of sorafenib or everolimus alone were noticeably present in both in vitro and in vivo studies and that their antitumor effects were significantly augmented by their combination, confirming the results of previous animal studies. (13, 14, 32, 33) However, contrary to our expectation, the antitumor effect of sorafenib alone was not identified in LT recipients with HCC recurrence. (9) Furthermore, any synergistic effect of combination therapy was not clearly demonstrated in LT recipients. According to the Korean clinical practice guidelines, sorafenib is the last therapeutic option for HCC because the social health insurance policy permits its use only after locoregional treatment is no longer applicable. Thus, the time of starting sorafenib administration was usually much delayed until definite local tumor progression or multiple metastases occurred. Through our clinical experience on sorafenib treatment (unpublished data), we recognized that the therapeutic efficacy of sorafenib is lower in non-LT patients with far advanced HCC compared with that in non-LT patients with less advanced HCC. In addition, sorafenib administration had to be stopped in patients showing disease progression during sorafenib treatment, and thereafter, they were usually provided only the best supportive care. Although we included patients with sorafenib treatment for 3 months in the sorafenib group, half of them had to stop sorafenib because of disease progression within 6 months. We presume that such a late and short-term administration of sorafenib was 1 of the main causes of its reduced therapeutic efficacy. If sorafenib had been administered in an earlier phase of HCC recurrence, we expect that its therapeutic efficacy might be improved. In contrast, the present study demonstrated that the antitumor effect of mTORi was evident in LT recipients, which was quite comparable with that of the in vivo mouse study. This finding on the antitumor effect of mTORi on established HCC recurrence was not reported before and is consistent with that of previous clinical studies on its preventive effect on HCC recurrence. (34) (35) (36) The nude mouse is athymic; thus, the depleted T-lymphocyte function facilitates tumor cell growth. In contrast, mTORi selectively inhibits only IL2-mediated T cell proliferation in normal human individuals; thus, tumor growth might be more suppressed in LT recipients than in the nude mouse model because their innate immunity against tumor cells may be well preserved. The mammalian target of rapamycin signaling pathways are associated with the carcinogenesis of human HCC; thus, its blockage by mTORi may also significantly contribute to tumor growth inhibition. (38) In addition to the innate antitumor effect of mTORi, elimination of tumor progression-prone effect from CNI should be taken into account. A half of our patients belonging to the mTORi group received mTORi monotherapy, and the other half of the patients were exposed to a very low concentration of CNI or mycophenolic acid.
A Korean single-institution study found that 12 patients who received combination therapy with sorafenib and sirolimus demonstrated better postrecurrence survival outcomes than 27 patients with best supportive care for posttransplant HCC recurrence. (12) In a Spanish multicenter study on 31 LT recipients with HCC recurrence, combination therapy resulted in partial response in 1 patient and stable disease in 13; thus, the overall clinical benefit rate was 53.8%. (39) However, considering the results of our present study, we presumed that such prognostic benefit might have been greatly influenced by mTORi rather than the combination therapy. To our knowledge, our study has the largest number of posttransplant HCC recurrence cases from a single institution and, to date, is the only clinical study to evaluate the individual antitumor effects of sorafenib and mTORi. Considering the poor outcomes of posttransplant HCC recurrence, it would be neither practical nor ethical to perform a controlled clinical study on this topic. Instead, to further validate our findings, it is necessary to perform multicenter studies.
In the non-LT setting, there was a randomized, double-blind, phase 3 study conducted among 546 adults with HCC of Barcelona Clinic Liver Cancer stage B or C and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib. No significant difference in overall and progression-free survival was seen between the everolimus and placebo groups, which implicated that the antitumor or synergistic effect of everolimus was absent in patients with advanced HCC whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib. (40) These results were contradictory to those of our clinical study, but we have to consider that there are 2 quite different settings as a non-LT setting not requiring immunosuppression and a LT setting inevitably requiring immunosuppression.
When administering combination therapy with sorafenib and mTORi in LT recipients, a high probability of adverse effects is anticipated. The 3-month dropout rate of sorafenib was 35.6% (42 of 118 patients) in our present study; sorafenib administration had to be stopped in 21 of these 42 patients within the first month primarily because of severe adverse effects even after dosage reduction. In contrast, mTORi administration had to be stopped in only 4 of 51 patients (7.8%) because of serious adverse effects because dosage reduction combined with other IS agents could effectively alleviate the adverse effects. It was noticeable that the dropout rate with everolimus treatment was noticeably decreased after it was covered by social health insurance. Therefore, if LT recipients can tolerate sorafenib, we think that it is not difficult to add mTORi because the adverse effects can be readily managed with dosage reduction. In contrast, for LT recipients who already administer mTORi, the add-on of sorafenib may not be as simple because of a high probability of adverse effects.
This study has some limitations. This was a retrospective single-center study in an HBV-endemic area, and a majority of our patients underwent living donor LT. Another major limitation is that the Korean health insurance policy permits the use of sorafenib only in patients who cannot receive locoregional treatment any longer. Thus, its administration was usually started at very advanced stages of HCC recurrence. The Korean health insurance policy also forced the use of everolimus and tacrolimus concurrently, which lowered the proportion of mTORi monotherapy in this study. Recently, everolimus monotherapy is selectively permitted in cases of HCC recurrence or de novo malignancy. A unique strong point of this study is that the survival status of all patients was completely followed up.
In conclusion, our laboratory study demonstrated individual and synergistic antitumor effects of sorafenib and mTORi, but this was not reproduced in our clinical LT study. Because our clinical result of mTORi administration with or without minimal CNI showed improved postrecurrence survival, administering mTORi in LT recipients with HCC recurrence appears worthwhile. However, the antitumor effect of sorafenib on posttransplant recurrence was not determined in this retrospective study, thus requiring further studies with an early start of sorafenib administration.
